Cullinan Oncology, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cullinan Oncology, Inc.
With valuations down and borrowing costs up, many industry insiders are expecting Darwinian scenes in biotech this year. Survival of the fittest is the order of the day: companies with riskier, less commercially defined propositions will struggle, while platform companies with multiple shots on strong goals will increasingly find favor in a more risk-averse environment.
Bristol Myers Squibb thinks Turning Point’s ROS1/TRK inhibitor shows a best-in-class profile and potential to compete more successfully against Pfizer’s Xalkori than Roche’s Rozlytrek has.
Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.
Glenmark is set to initiate a Phase I study for its inhibitor of immuno-oncology target hematopoietic progenitor kinase 1 (HPK1), a segment that has seen increased activity over the recent past with BeiGene, Nimbus and Treadwell Therapeutics among those advancing their molecules.
- Large Molecule
- Other Names / Subsidiaries
- Cullinan Florentine
- Cullinan Management, Inc.
- Cullinan MICA
- Cullinan Pearl
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.